PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Patients with age ≥ 18 years

• diagnosis of lung cancer,head and neck cancer,colorectal cancer,ovarian cancer

• Karnofsky Performance Status ≥ 70

• life expectancy of at least 3 months

• Written informed consent are acquired

Exclusion Criteria:

• uncontrolled infection,Temperature is 38.0 ℃ or higher

• pregnancy

• Other situations that investigators consider as contra-indication for this study